2020 Q1 Form 10-Q Financial Statement
#000156459020021920 Filed on May 06, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $3.570M | $2.360M |
| YoY Change | 51.27% | -45.24% |
| % of Gross Profit | ||
| Research & Development | $5.498M | $104.0K |
| YoY Change | 5186.54% | -99.01% |
| % of Gross Profit | ||
| Depreciation & Amortization | $171.0K | $41.00K |
| YoY Change | 317.07% | |
| % of Gross Profit | ||
| Operating Expenses | $9.071M | $2.659M |
| YoY Change | 241.14% | -82.05% |
| Operating Profit | -$9.071M | |
| YoY Change | ||
| Interest Expense | $450.0K | $450.0K |
| YoY Change | 0.0% | 80.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $429.0K | $451.0K |
| YoY Change | -4.88% | 132.47% |
| Pretax Income | -$8.640M | -$2.210M |
| YoY Change | 290.95% | -84.88% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$8.642M | -$2.208M |
| YoY Change | 291.39% | -84.9% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.18 | |
| Diluted Earnings Per Share | -$0.18 | -$93.88K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 49.17M shares | 23.54M shares |
| Diluted Shares Outstanding | 49.17M shares |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $139.4M | $74.20M |
| YoY Change | 87.87% | -19.96% |
| Cash & Equivalents | $139.9M | $74.17M |
| Short-Term Investments | ||
| Other Short-Term Assets | ||
| YoY Change | ||
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $200.0K | $700.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $139.7M | $74.83M |
| YoY Change | 86.69% | -20.58% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $12.40M | $359.0K |
| YoY Change | 3354.04% | -57.71% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $500.0K | $0.00 |
| YoY Change | -100.0% | |
| Total Long-Term Assets | $13.40M | $603.0K |
| YoY Change | 2122.22% | -56.93% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $139.7M | $74.83M |
| Total Long-Term Assets | $13.40M | $603.0K |
| Total Assets | $153.1M | $75.43M |
| YoY Change | 102.96% | -21.11% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.000M | $3.400M |
| YoY Change | 47.06% | -63.83% |
| Accrued Expenses | $500.0K | $200.0K |
| YoY Change | 150.0% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $100.0K | |
| YoY Change | ||
| Total Short-Term Liabilities | $5.603M | $3.596M |
| YoY Change | 55.81% | -61.56% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $100.0K | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $10.20M | $4.000K |
| YoY Change | 254900.0% | -99.1% |
| Total Long-Term Liabilities | $10.30M | $4.000K |
| YoY Change | 257400.0% | -99.1% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $5.603M | $3.596M |
| Total Long-Term Liabilities | $10.30M | $4.000K |
| Total Liabilities | $15.93M | $3.892M |
| YoY Change | 309.33% | -60.28% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$308.2M | -$232.3M |
| YoY Change | 32.66% | 8.99% |
| Common Stock | $0.00 | $0.00 |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $137.1M | $71.54M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $153.1M | $75.43M |
| YoY Change | 102.89% | -21.11% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$8.642M | -$2.208M |
| YoY Change | 291.39% | -84.9% |
| Depreciation, Depletion And Amortization | $171.0K | $41.00K |
| YoY Change | 317.07% | |
| Cash From Operating Activities | -$6.440M | -$2.756M |
| YoY Change | 133.67% | -82.32% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $107.0K | $0.00 |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | -$107.0K | $0.00 |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $3.390M | -2.000K |
| YoY Change | -169600.0% | -101.01% |
| NET CHANGE | ||
| Cash From Operating Activities | -$6.440M | -2.756M |
| Cash From Investing Activities | -$107.0K | 0.000 |
| Cash From Financing Activities | $3.390M | -2.000K |
| Net Change In Cash | -$3.168M | -2.759M |
| YoY Change | 14.82% | -118.93% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$6.440M | -$2.756M |
| Capital Expenditures | $107.0K | $0.00 |
| Free Cash Flow | -$6.547M | -$2.756M |
| YoY Change | 137.55% | -82.37% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
98102 | |
| CY2020Q1 | nltx |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
236000 | |
| CY2019Q4 | nltx |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
503000 | |
| CY2020Q1 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
5003000 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4125000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
447000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
146000 | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
15931000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
59000 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
||
| CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
62000 | |
| CY2019Q1 | nltx |
Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
|
104000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
5336000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5603000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
146000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
541000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4743000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10182000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
556000 | |
| CY2020Q1 | nltx |
Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
|
5498000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
||
| CY2020Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
445291000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
441216000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-308171000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-299529000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
137120000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
141687000 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
153051000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
147023000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38386160 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37996849 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38386160 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37996849 | |
| CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2555000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3573000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
9071000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.09 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2756000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2659000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
429000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
451000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8642000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2208000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
49168451 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23537368 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8642000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2208000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-8642000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-2208000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
683000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1078000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
171000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
41000 | |
| CY2020Q1 | nltx |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
528000 | |
| CY2019Q1 | nltx |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
21000 | |
| CY2020Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
14000 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-12000 | |
| CY2020Q1 | nltx |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
-266000 | |
| CY2019Q1 | nltx |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
403000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
568000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-1297000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6440000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
107000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-107000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3392000 | |
| CY2020Q1 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
2000 | |
| CY2019Q1 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
2000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3390000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2000 | |
| CY2020Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-11000 | |
| CY2019Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-1000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3168000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2759000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
143093000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
76928000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
139925000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
74169000 | |
| CY2020Q1 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
435000 | |
| CY2019Q1 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
443000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3392000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
683000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72672000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1078000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71542000 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of operations </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neoleukin Therapeutics, Inc. (“Neoleukin” or “the Company”) is<font style="color:#000000;"> a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using</font><font style="font-style:italic;color:#000000;"> de novo </font><font style="color:#000000;">protein design technology. Neoleukin uses sophisticated computational methods to design</font><font style="font-style:italic;color:#000000;"> </font><font style="Background-color:#FFFFFF;">proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company commenced operations in Canada in December 2003. Aquinox Pharmaceuticals (Canada) Inc., a corporation formed under the Canada Business Corporations Act, is a wholly owned subsidiary of Aquinox Pharmaceuticals, Inc., a Delaware corporation formed in May 2007 (“Aquinox”). </font><font style="color:#000000;">On August 8, 2019, upon the merger of Aquinox with Neoleukin Therapeutics, Inc. (“Former Neoleukin”) pursuant to an Agreement and Plan of Merger dated August 5, 2019, Former Neoleukin merged with a wholly owned subsidiary of Aquinox. Upon completion of the transaction, Aquinox was renamed Neoleukin Therapeutics, Inc. </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s head office is in Seattle, Washington.</p> | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(b) Use of estimates and assumptions</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical and other accruals. Actual results could differ from those estimates.</p> | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
60000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
300000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
60000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
12000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
528000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
242000 | |
| CY2020Q1 | nltx |
Number Of Annual Payments
NumberOfAnnualPayments
|
5 | |
| CY2020Q2 | nltx |
Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
|
118200000 | |
| CY2019Q4 | nltx |
Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
|
40000000 | |
| CY2020Q1 | us-gaap |
Security Deposit
SecurityDeposit
|
500000 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
500000 | |
| CY2019Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | |
| CY2020Q1 | us-gaap |
Cash
Cash
|
21200000 | |
| CY2019Q4 | us-gaap |
Cash
Cash
|
103100000 | |
| CY2020Q1 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
118200000 | |
| CY2019Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
40000000 | |
| CY2019Q4 | us-gaap |
Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
|
8000000 | |
| CY2019Q4 | nltx |
Additional Tenant Improvements
AdditionalTenantImprovements
|
1500000 | |
| CY2020Q1 | nltx |
Finance Lease Liability Aggregate Purchase Price Of Asset
FinanceLeaseLiabilityAggregatePurchasePriceOfAsset
|
300000 | |
| CY2020Q1 | nltx |
Lease Expiration Month Year
LeaseExpirationMonthYear
|
2023-06 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
74000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
37000 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y6M21D | |
| CY2019Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
48000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
205000 | |
| CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
300000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
414000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
31000 | |
| CY2020Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
28000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2502000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2086000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2139000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
2192000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
9124000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
62000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
60000 | |
| CY2020Q1 | us-gaap |
Lease Cost
LeaseCost
|
642000 | |
| CY2019Q1 | us-gaap |
Lease Cost
LeaseCost
|
79000 | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y1M13D | |
| CY2019Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y5M1D | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y1M9D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y6M29D | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0711 | |
| CY2019Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0694 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.1263 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0600 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
310000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
41000 | |
| CY2020Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
2000 | |
| CY2019Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
2000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
9614000 | |
| CY2019Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
515000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
18457000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
7734000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
10723000 | |
| CY2020Q1 | nltx |
Stock Shares Authorized Net
StockSharesAuthorizedNet
|
105000000 | |
| CY2019Q4 | nltx |
Stock Decrease Increase During Period Shares Conversion Of Common Stock To Prefunded Warrants
StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants
|
10925481 | |
| CY2020Q1 | nltx |
Common Stock Reserved For Issuance Description
CommonStockReservedForIssuanceDescription
|
Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. | |
| CY2020Q1 | nltx |
Period Shares Reserved For Issuance Will Increase
PeriodSharesReservedForIssuanceWillIncrease
|
P10Y | |
| CY2020Q1 | nltx |
Stock Based Compensation Increase In Common Stock Issuance Percentage
StockBasedCompensationIncreaseInCommonStockIssuancePercentage
|
0.04 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5840538 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
290700 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
376311 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
410000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5344927 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1040512 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.11 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
7.63 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
9.03 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
16.91 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.06 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
7.28 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M19D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y8M12D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
45037000 | |
| CY2019Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
6700000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y4M9D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
5462000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1300000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
40431000 | |
| CY2019Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7M9D | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.90 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y18D | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0078 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.62 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
9800000 | |
| CY2020Q1 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
434000 | |
| CY2019Q1 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
450000 | |
| CY2020Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
15000 | |
| CY2019Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
2000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
20000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
1000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5478927 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2633197 |
